Comprehensive Study Guide to Water-Soluble B-Vitamins (B5, B6, B7, B9, and B12)

Vitamin B5 (Pantothenic Acid)

• Chemical Forms and Precursors:

  • Vitamin B5 is universally known as pantothenic acid.

  • It consists of pantoic acid linked via an amide bond to $\beta$-alanine.

• Absorption and Transport Mechanics:

  • Pantothenic acid is ingested and absorbed in two primary forms:

  • Free pantothenic acid molecules.

  • Covalently bound forms within coenzyme A (CoA) and CoA esters.

  • In the lumen of the small intestine, dietary CoA is enzymatically degraded to release free pantothenic acid.

  • Cellular uptake into enterocytes and subsequent passage into blood plasma occurs via Sodium-Dependent Multivitamin Transporters (SMVT).

• Metabolic Functions:

  • Plays an essential role as a biochemical precursor for the synthesis of Coenzyme A (CoA).

  • Supplies the CoA component needed to generate acetyl-CoA molecules, which enter central metabolic pathways for carbohydrate, lipid, and amino acid oxidation.

• Deficiency Manifestations:

  • Characteristic disorder: Burning feet syndrome, accompanied by lower extremity numbness and tingling (paresthesia).

  • Systemic failure of cellular energy metabolism, presenting as:

  • Severe fatigue.

  • Impaired hepatic and muscular glycogen storage.

  • Potential development of hypoglycemia.

• Dietary Recommendations and Stability:

  • No Recommended Dietary Intake (RDI) is established; requirements are defined by Adequate Intake (AI):

  • Men: $6\,\text{mg/day}$

  • Women: $4\,\text{mg/day}$

  • Pregnancy: $5\,\text{mg/day}$

  • Lactation: $6\,\text{mg/day}$

  • Upper Level of Tolerable Intake (UL): Not set.

  • Processing sensitivity: Widely distributed across food supplies, but highly labile and easily inactivated by heating and freezing. Refining cereal grains reduces pantothenic acid content by $75\%$.

Vitamin B6 (Pyridoxine, Pyridoxal, Pyridoxamine)

• Chemical Forms and Interconversions:

  • Vitamin B6 represents a family of chemically interchangeable vitramers:

  1. Pyridoxine (PN) — the primary vitramer found in plant tissues.

  2. Pyridoxal (PL) — aldehyde form.

  3. Pyridoxamine (PM) — aminated form.

  • Active coenzyme forms (predominantly present in animal tissues as $5'$- phosphate derivatives):

  • Pyridoxine $5'$- phosphate (PNP).

  • Pyridoxal $5'$- phosphate (PLP) — the principal coenzyme form.

  • Pyridoxamine $5'$- phosphate (PMP).

  • Plant storage form: Pyridoxine $5'$ -$\beta$ -D-glucoside (PNG).

  • Metabolic excretion: Interconverted by PL kinase, phosphatases, PNP oxidase, and transaminases, ultimately converted via aldehyde dehydrogenase to 4-pyridoxic acid for urinary excretion.

• Absorption, Transport, and Tissue Storage:

  • Free unphosphorylated forms (PN, PL, PM) are absorbed in the jejunum via passive diffusion.

  • Bioavailability profile:

  • Non-glucoside forms exhibit high bioavailability ($>75\%$).

  • Plant-derived pyridoxine $5'$ -$\beta$ -D-glucoside exhibits significantly reduced intestinal bioavailability.

  • Metabolism: Most absorbed B6 is taken up by the liver and phosphorylated to form PLP.

  • Transport: PLP enters systemic circulation bound to circulating albumin complexes.

  • Storage: Reservoirs reside primarily in skeletal muscle tissue bound tightly to the enzyme glycogen phosphorylase.

• Enzymatic Functions and Coenzyme Roles:

  • Serves as a cofactor for over 100 enzymatic reactions across human metabolism.

• Transamination reactions: Transfers amino groups to keto-acids for amino acid synthesis and interconversion. Without Vitamin B6, all amino acids become nutritionally essential.

• Glycogenolysis: Coenzyme for muscle glycogen phosphorylase, catalyzing glycogen breakdown.

• Lipid synthesis: Cofactor in fatty acid and phospholipid metabolic pathways.

• Neurotransmitter and hormone synthesis: Coenzyme for decarboxylase enzymes involved in synthesizing epinephrine, serotonin, and dopamine.

• Homocysteine degradation: Catalyzes transsulfuration of homocysteine to prevent toxic accumulation.

  • Deficiency States and Risk Factors:

• Microcytic anemia: Inadequate PLP impairs $\delta$ -aminolevulinic acid synthase, decreasing hemoglobin synthesis and resulting in microcytic, hypochromic red blood cells.

• Neurological disturbances: Impaired synthesis of neurotransmitters causes convulsions, depression, and confusion.

• Hyperhomocysteinemia: Inefficient degradation leads to elevated vascular homocysteine, raising cardiovascular disease risk.

• Alcoholism: Chronic alcohol consumption causes poor nutritional intake and ethanol-induced liver injury that inhibits B6 conversion to PLP.

  • Toxicity and Recommended Intake:

• Dietary toxicity is rare, but high-dose supplementation induces sensory peripheral neuropathy. A Tolerable Upper Intake Level (UL) is established.

• Reference values:

  • Men: RDI $1.3\text{--}1.7\,\text{mg/day}$, UL $50\,\text{mg/day}$

  • Women: RDI $1.3\text{--}1.5\,\text{mg/day}$, UL $50\,\text{mg/day}$

  • Pregnancy: RDI $1.9\,\text{mg/day}$, UL $40\text{--}50\,\text{mg/day}$

  • Lactation: RDI $2.0\,\text{mg/day}$, UL $40\text{--}50\,\text{mg/day}$

• Sensitivity: Thermal processing during cooking degrades Vitamin B6.

  • Food Sources:

• Rich sources include raw bananas ($1\text{ medium}, 458\,\text{kJ} \approx 0.7\,\text{mg}$), roasted chicken breast ($85\,\text{g}, 588\,\text{kJ} \approx 0.6\,\text{mg}$), baked potatoes with skin ($1\text{ medium}, 559\,\text{kJ} \approx 0.4\,\text{mg}$), canned tuna, prune juice, bluefish, and squash.

Vitamin B7 (Biotin)

• Chemical Structure and Precursors:

  • Synthesized by microorganisms (including resident colonic microbiota) and plants.

  • Present in food matrices as free biotin or bound covalently to proteins.

  • Protein-bound biotin is released during digestion as biocytin (biotinyl-lysine), which requires cleavage by biotinidase to release free biotin.

• Digestion and Intestinal Transport:

  • Gastric and pancreatic proteases/peptidases breakdown protein complexes to yield biocytin and free biotin.

  • Biotinidase releases free biotin from biocytin.

  • Absorption occurs in the small intestine via Sodium-Dependent Multivitamin Transporters (SMVT).

  • Free biotin is absorbed at a higher efficiency rate than biocytin.

  • Under biotin-deprived conditions, intestinal expression of SMVT is upregulated to increase absorption capacity.

  • Transported in systemic circulation as free biotin for uptake by extrahepatic tissues.

• Metabolic Functions:

  • Essential coenzyme for biotin-dependent carboxylase enzymes, which transfer carbon dioxide carboxyl groups ($\text{CO}_2$):

  • Pyruvate carboxylase: Converts pyruvate into oxaloacetate to initiate and maintain the tricarboxylic acid (TCA) cycle.

  • Acetyl-CoA carboxylase: Catalyzes the rate-limiting step in fatty acid synthesis.

• Deficiency Etiology and Clinical Manifestations:

  • Clinical deficiency is rare, but occurs under specific conditions:

  • Consumption of excessive raw egg whites: Raw egg whites contain avidin, a glycoprotein that binds biotin with extreme affinity, preventing intestinal uptake. Heat cooking denatures avidin, eliminating this binding.

  • Inborn errors of metabolism: Genetic deficiency of biotinidase prevents liberation of free biotin from dietary protein sources.

  • Deficiency symptoms: Dermatitis, conjunctivitis, central nervous system impairment (lethargy, hallucinations), and alopecia (hair loss). Treatment involves pharmacological doses of oral biotin.

• Recommended Intake:

  • Adequate Intake (AI) parameters:

  • Men: $30\,\mu\text{g/day}$

  • Women: $25\,\mu\text{g/day}$

  • Pregnancy: $30\,\mu\text{g/day}$

  • Lactation: $35\,\mu\text{g/day}$

  • Upper Level of Tolerable Intake (UL): Not set.

Vitamin B9 (Folate)

• Nomenclature and Chemical Forms:

  • Folate is a generic term encompassing multiple pteroylglutamate derivatives:

  • Folic acid: Synthetic oxidized monoglutamate form used in dietary supplements and food fortification.

  • Food Folates: Naturally occurring reduced polyglutamate forms, predominantly tetrahydrofolate (THF) derivatives.

• Digestion, Bioavailability, and Absorption:

  • Enzymatic digestion: Polyglutamate food folates must be hydrolyzed to monoglutamate forms at the intestinal brush border membrane by glutamate carboxypeptidase II.

  • Site of absorption: Duodenum and upper jejunum where luminal pH is acidic.

  • Transport mechanisms:

  • Low luminal concentration: Mediated by Proton-Coupled Folate Transporters (PCFT) operating at optimal low pH.

  • High concentration: Passive diffusion across the enterocyte membrane.

  • Bioavailability comparison:

  • Synthetic folic acid displays significantly higher bioavailability than natural food folates.

  • Natural folates are trapped inside fibrous cell structures, susceptible to breakdown in gastric fluid, and sensitive to higher intestinal pH.

  • Excessive high-dose supplementation is constrained by limited tissue retention and metabolic capacity.

  • Transport: Absorbed monoglutamates enter portal circulation to the liver. The liver releases THF into plasma and excretes a portion into bile for enterohepatic circulation.

• Functions in DNA Synthesis and One-Carbon Metabolism:

  • Single-carbon transfer reactions: THF acts as a coenzyme transferring one-carbon units needed for nucleotide synthesis.

  • DNA replication: Converts deoxyuridylate (dUMP) to thymidylate (dTMP), required for cellular DNA synthesis, replication, and structural repair.

  • Folic Acid Cycle: Functions synergistically with Vitamin B12 in remethylating homocysteine to methionine.

• Deficiency Pathophysiology:

  • Etiology: Inadequate intake, malabsorption, pharmacological inhibition (e.g., methotrexate, aspirin, antacids), or genetic mutations.

  • Genetic polymorphism: The C677T point mutation in the methylenetetrahydrofolate reductase (MTHFR) gene affects $2\text{--}16\%$ of Caucasian populations, reducing MTHFR activity and elevating dietary folate demands.

  • Megaloblastic Anemia:

  • Characterized by oversized, morphologically abnormal red blood cells (macrocytes).

* Mechanism: Impaired dTMP synthesis blocks DNA strand replication and cell division. RNA synthesis and cytoplasmic growth proceed uninterrupted, producing large cells with immature nuclei containing double the normal DNA content.

* Symptoms: Fatigue, weakness, irritability, headaches, and glossitis (smooth, painful red tongue).

• Neural Tube Defects (NTDs):

  • Incomplete closure of the embryonic neural tube/spinal cord during early gestation (e.g., spina bifida).

* Prevention: Maternal preconception and early trimester supplementation reduces NTD risk. Mandatory fortification of wheat flour with folic acid serves as a public health protection measure.

• Recommended Intake and Food Sources:

  • Measured as Dietary Folate Equivalents (DFE):

  • Men: RDI $400\,\mu\text{g DFE/day}$, UL $1000\,\mu\text{g DFE/day}$

  • Women: RDI $400\,\mu\text{g DFE/day}$, UL $1000\,\mu\text{g DFE/day}$

  • Pregnancy: RDI $600\,\mu\text{g DFE/day}$, UL $800\text{--}1000\,\mu\text{g DFE/day}$

  • Lactation: RDI $500\,\mu\text{g DFE/day}$, UL $800\text{--}1000\,\mu\text{g DFE/day}$

  • Food sources:

• Rich sources include cooked lentils ($\frac{1}{2}\text{ cup}, 483\,\text{kJ} \approx 180\,\mu\text{g}$), cooked asparagus ($\frac{1}{2}\text{ cup}, 92\,\text{kJ} \approx 130\,\mu\text{g}$), dark green leafy vegetables (cooked broccoli), legumes (cooked pinto beans), fortified cereals (cornflakes: $30\,\text{g}, 462\,\text{kJ} \approx 100\,\mu\text{g}$), and orange juice.

Vitamin B12 (Cobalamin)

• Chemical Structure and Vitramers:

  • Corrin ring structure surrounding a central trivalent cobalt ion ($Co^{3+}$), attached to an aminoisopropanol linker, ribose 3-phosphate, and a dimethylbenzimidazole nucleotide.

• Coenzyme forms:

  • Methylcobalamin ($\text{X} = -\text{CH}_3$).

  • 5'-Deoxyadenosylcobalamin ($\text{X} = 5'\text{-deoxyadenosyl}$).

• Other variants:

  • Hydroxylcobalamin ($\text{X} = -\text{OH}/\text{H}_2\text{O}$).

  • Cyanocobalamin ($\text{X} = -\text{CN}$) — synthetic supplemental and pharmaceutical form.

  • Multi-Step Gastrointestinal Absorption Pathway:

• Gastric Release: Protein-bound dietary cobalamin is released from food matrix proteins by gastric acid ($\text{HCl}$) and pepsin cleavage in the stomach. (Free cobalamin in fortified foods bypasses peptic release).

• Haptocorrin Binding: Released B12 binds to haptocorrin (R-protein/cobalamin-binding protein), secreted by salivary glands and gastric parietal cells, forming an acid-stable B12-haptocorrin complex.

• Proteolytic Cleavage in Small Intestine: The complex passes into the duodenum, where pancreatic proteases degrade haptocorrin, releasing free cobalamin.

• Intrinsic Factor Binding: Free B12 binds to Intrinsic Factor (IF), a glycoprotein produced by gastric parietal cells, forming a stable B12-IF complex.

• Ileal Receptor Uptake: The B12-IF complex moves to the distal ileum, binding to cubulin receptors (ileal B12-IF receptors) on enterocytes, and is absorbed via receptor-mediated endocytosis.

• Absorption Dynamics and Bioavailability:

  • Receptor saturation limits active absorption: Doses $\le 3\,\mu\text{g}$ exhibit $\approx 50\%$ absorption, with fractional efficiency declining at higher intakes.

  • Passive diffusion: $\approx 1\%$ of high pharmacological doses is absorbed via non-receptor passive diffusion.

• Metabolic Functions:

  • Remethylation of Homocysteine: Methylcobalamin acts as a required coenzyme for methionine synthase, receiving a methyl group from 5-methyl-THF and transferring it to homocysteine, producing methionine and regenerating active THF.

  • Interconnection with Folate: Critical for converting trapped folate derivatives into active coenzyme forms required for DNA synthesis.

• Deficiency States and Clinical Manifestations:

  • Etiology: Prevalent in elderly populations ($\ge 65\text{ years}$) and strict vegans (since B12 is produced exclusively by bacteria and present naturally only in animal foods).

  • Pernicious Anemia: Autoimmune destruction of gastric parietal cells causing loss of Intrinsic Factor (IF) production and severe B12 malabsorption (associated with atrophic gastritis or gastrectomy).

  • Megaloblastic Anemia: Morphologically identical to folate-deficiency anemia due to functional trapping of folate as 5-methyl-THF.

  • Neurological Pathology: B12 is required for maintaining myelin sheath integrity around nerve axons. Deficiency produces progressive demyelination, causing peripheral neuropathy, paresthesia, loss of coordination, memory loss, dementia, and depression.

  • Systemic Symptoms: Fatigue, weakness, irritability, headaches, and glossitis.

• Recommended Intake and Food Distribution:

  • Dietary Parameters:

  • Men: RDI $2.4\,\mu\text{g/day}$

  • Women: RDI $2.4\,\mu\text{g/day}$

  • Pregnancy: RDI $2.6\,\mu\text{g/day}$

  • Lactation: RDI $2.8\,\mu\text{g/day}$

  • Tolerable Upper Intake Level (UL): Not set (low toxicity potential).

  • Food sources: Present naturally exclusively in animal-derived products (red meat, poultry, fish, eggs, milk, and dairy items). Strict vegans must consume fortified foods or daily dietary supplements.